Czempik Katarzyna, Noster Izabela, Dziaczkowska-Suszek Joanna, Glowala-Kosinska Magdalena, Kata Dariusz, Kopinska Anna, Helbig Grzegorz
Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland.
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
J Hematol. 2025 Apr;14(2):79-85. doi: 10.14740/jh2022. Epub 2025 Feb 21.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many hematologic disorders, and donor cell leukemia (DCL) remains a complication rarely observed after HSCT. The number of reported cases of DCL slightly exceeds 100, with acute myeloid leukemia (AML) being the most common type. To date, only a few cases of chronic lymphocytic leukemia (CLL) emerging from donor cells have been described in the literature. Here, we report two cases of CLL of donor origin, which emerged in patients after HSCT for AML. In the reported cases, patients maintained complete remission of AML after HSCT. Both donors were free of CLL before transplantation. Several years after HSCT (9 and 3 years, respectively), lymphocytosis with proven B-cell clonality was detected in recipients prompting a detailed blood analysis to be performed also in donors. CLL population was demonstrated in both cases. The first donor-recipient pair did not meet criteria for CLL treatment and eventually died from causes not related to underlying hematologic malignancy. The second couple received Bruton's tyrosine kinase inhibitors with good disease control. The presented cases raise the question of possible clonal evolution of B-lymphocytes in donor-origin cells. Prospective screening of potential donors for pre-malignant alterations remains a matter of discussion.
异基因造血干细胞移植(HSCT)是治疗多种血液系统疾病的一种治愈性方法,而供体细胞白血病(DCL)仍然是HSCT后很少观察到的一种并发症。报道的DCL病例数略超过100例,其中急性髓系白血病(AML)是最常见的类型。迄今为止,文献中仅描述了少数几例源自供体细胞的慢性淋巴细胞白血病(CLL)病例。在此,我们报告两例供体来源的CLL病例,它们出现在接受AML HSCT后的患者中。在报告的病例中,患者在HSCT后维持AML完全缓解。两名供体在移植前均无CLL。HSCT数年之后(分别为9年和3年),在受者中检测到淋巴细胞增多且证实具有B细胞克隆性,这促使对供体也进行详细的血液分析。两例均证实存在CLL群体。第一对供体 - 受体不符合CLL治疗标准,最终死于与潜在血液系统恶性肿瘤无关的原因。第二对接受了布鲁顿酪氨酸激酶抑制剂治疗,疾病得到良好控制。所呈现的病例提出了供体来源细胞中B淋巴细胞可能发生克隆进化的问题。对潜在供体进行恶性前改变的前瞻性筛查仍是一个有待讨论的问题。